Single arm (ganciclovir and valganciclovir)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cytomegalovirus Infection
Conditions
Cytomegalovirus Infection
Trial Timeline
Mar 1, 2004 → Jul 1, 2008
NCT ID
NCT00730769About Single arm (ganciclovir and valganciclovir)
Single arm (ganciclovir and valganciclovir) is a approved stage product being developed by Roche for Cytomegalovirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00730769. Target conditions include Cytomegalovirus Infection.
What happened to similar drugs?
6 of 20 similar drugs in Cytomegalovirus Infection were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00730769 | Approved | Completed |
Competing Products
20 competing products in Cytomegalovirus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 3 | 0 |
| ASP0113 + Placebo | Astellas Pharma | Phase 2 | 35 |
| ASP0113 + Placebo | Astellas Pharma | Phase 3 | 40 |
| Letermovir oral granules + Letermovir tablet + Letermovir intravenous | Merck | Phase 2 | 35 |
| Letermovir 240 mg Oral Tablet | Merck | Phase 2 | 42 |
| Letermovir tablet + Letermovir IV | Merck | Phase 3 | 40 |
| Letermovir | Merck | Phase 1 | 36 |
| Letermovir | Merck | Approved | 43 |
| Letermovir 480 MG [Prevymis] | Merck | Phase 2 | 42 |
| V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID | Merck | Phase 1 | 29 |
| Ganciclovir | Merck | Pre-clinical | 26 |
| Letermovir + Placebo | Merck | Phase 3 | 40 |